latest news releases from the newsroom
Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma
STOCKHOLM, Sweden and SAN DIEGO, Nov. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that based upon the negative outcome of it's confirmatory Phase 3 clinical trial (M0104) studying Ceplene(tm) (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) in advanced malignant melanoma patients with liver metastases, it plans to close the treatment protocol approved by the FDA earlier this year. The treatment protocol allowed Maxim to provide expanded access of Ceplene(tm) therapy to advanced malignant melanoma patients while investigation of the drug continued in the confirmatory M0104 clinical trial. Any patient currently enrolled in the treatment protocol will be allowed to complete their treatment regimen under a compassionate use program. Maxim also intends to withdraw its pending U.S. New Drug Application seeking approval of Ceplene therapy to treat advanced malignant melanoma patients with liver metastases.
Tele2: Disclosure Notice
STOCKHOLM, Sweden and NEW YORK, Nov. 1, 2004 (PRIMEZONE) -- Tele2 AB (Reg. No. 556410-8917) (Nasdaq:TLTOA) (Nasdaq:TLTOB) (Stockholm:TEL2A) (Stockholm:TEL2B) has on October 29, 2004 sold 9,460,000 shares in Song Networks Holding AB, representing 18.0% of the votes and 17.0% of the capital in the company. After the sale Tele2 AB, directly or indirectly, does not hold any shares in Song Networks Holding AB.
Metro Helsinki Named 'Most Creative Media of 2004'
BERTRANGE, Luxembourg, Nov. 1, 2004 (PRIMEZONE) -- Metro International S.A. ("Metro"), the international newspaper group, today announced that its Helsinki edition won the 'Most Creative Media of 2004' award from the Finnish Association of Marketing Communication Agencies (MTL). The award was made to Metro for its contribution during the year to the development of successful commercial advertising campaigns through creative and innovative formats.
ASM International NV
ASM International N.V. Introduces Enabling Process For Ultra Low-K
BILTHOVEN, The Netherlands, Nov. 1, 2004 (PRIMEZONE) -- ASM International N.V. (Nasdaq:ASMI) (Euronext Amsterdam:ASM) announced today the introduction of a breakthrough process, available on ASM's established Eagle(R) PECVD system, that enables the integration of next generation, porous low-k insulator materials in copper interconnect on semiconductor chips. The unique Plasma BCB Polymerization Technology was developed jointly with one of the major semiconductor device manufacturers. It has already been proven as a "Pore Sealing Process" and is targeted for implementation in the 65 nm manufacturing process. In addition to ASM's Aurora(R) Ultra Low-k (ULK) material, the Plasma BCB Deposition Process will work on most other industry-developed low-k PECVD dielectrics and an-organic spin-on dielectrics.
Skanska sells Ektorp Centrum in Nacka with a gain of SEK 63 M
STOCKHOLM, Sweden, Nov. 01, 2004 (PRIMEZONE) -- Skanska Project Development Sweden is selling the Sicklaon 354:1 and 354:2 properties in Nacka for SEK 30 M and SEK 70 M respectively. The buyer is Arvid Svensson Invest in cooperation with Altira in a jointly owned company Celeritas Fastigheter AB. The capital gain amounts to SEK 63 M and is being reported in the fourth quarter of 2004. The buyer will take possession of the properties in November 2004 at which time payment will be made.
PRUDENTIAL -- video interview with Asia CEO
LONDON, Nov. 1, 2004 (PRIMEZONE) -- Prudential Corporation Asia - Business Update. Indepth interview available now on www.cantos.com with Mark Norbom, Chief Executive, Prudential Corporation Asia (LSE:PRU)
AB Volvo announces share repurchase
GOTEBORG, Sweden, Nov. 01, 2004 (PRIMEZONE) -- Further to the decision taken by AB Volvo's Board of Directors on June 17, 2004, regarding repurchase of own shares, AB Volvo has, on Friday, October 29, acquired 250,000 series B shares. The shares were traded between SEK 267.50 and 269.50 with an average price of SEK 268.78.
Emerson Poynter LLP
Emerson Poynter LLP Announces Investigation in the ACE LTD., USA ERISA Retirement Plan -- ACE
HOUSTON, Oct. 30, 2004 (PRIMEZONE) -- Emerson Poynter LLP, a national law firm with offices in Houston, Little Rock, and Seattle (http://www.emersonpoynter.com) announced today that it had commenced an investigation regarding ACE Ltd.'s ("ACE" or the "Company") (NYSE:ACE) alleged violations of Federal and State securities laws and the Employee Retirement Income Security Act of 1974 ("ERISA") in relation to ACE's handling of investments in the Company's employee retirement benefit plan (the "Plans").